EGFR and non-small cell lung carcinoma: In patients with non-small cell lung cancer (NSCLC) bearing epithelial growth factor receptor (EGFR) activating/sensitive mutations, such as L858R and exon 19 deletions, EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been highly effective in approximately 70% of cases [2,3].